Abstract
Background: Istradefylline is a selective adenosine A2A receptor antagonist indicated in the USA and Japan as adjunctive treatment to a levodopa/decarboxylase inhibitor (LD) in adults with PD experiencing OFF time. This post-hoc analysis evaluated clinical effects of istradefylline as adjunctive treatment to LD in PD patients with or without additional anti-PD medications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
